読み込み中
NASDAQHealthcareBiotechnology
最新データ
$9.08
−$0.14 · -1.52%
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
前日終値
$9.08
−$0.14 · -1.52%
日中の時刻はETです。市場データは遅延する場合があります。
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
日中レンジ
現在 $9.08
52週レンジ
現在 $9.08
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
62
強気
リスク
63
高リスク
モメンタム
48
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
日中レンジ
現在 $9.08
52週レンジ
現在 $9.08
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 研究開発 | 4887.7万 EUR | 3931万 EUR | 2631.1万 EUR | 1942.1万 EUR |
| 販売・一般管理 | 1257.2万 EUR | 982.2万 EUR | 599.7万 EUR | 449万 EUR |
| 営業費用 | 5927.5万 EUR | 4802.1万 EUR | 3119万 EUR | 2263.4万 EUR |
| 受取利息 | 160.9万 EUR | 121.8万 EUR | 24.5万 EUR | 7.1万 EUR |
| 支払利息 | 6万 EUR | 6.7万 EUR | 3.1万 EUR | 4.5万 EUR |
| 減価償却費と償却費 | 21.9万 EUR | 31.1万 EUR | 9.9万 EUR | 2.3万 EUR |
| 営業利益 | −5927.5万 EUR | −4802.1万 EUR | −3119万 EUR | −2263.4万 EUR |
| 純利益 | −6254.7万 EUR | −4626.7万 EUR | −1139万 EUR | −814.2万 EUR |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$35.00
上昇余地（285.46%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
